Developer docs
API playgroundTry for free, no card

Search company profiles

COI Pharmaceuticals

Full company profile

uuid000qfes

Namestring
COI Pharmaceuticals
Websiteurl
coipharma.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

COI Pharmaceuticals, operating as COI Pharma, is a venture-pharma entity headquartered in San Diego, California, founded in 2013. The company operates with a small team of 11-50 employees and is structured as a private for-profit enterprise. The "venture-pharma" designation indicates the company functions as a pharmaceutical venture creation, asset-holding, or development platform rather than a vertically integrated commercial-stage drug developer — a structure typical of entities that identify, incubate, and progress therapeutic programs toward partnership, licensing, or spin-out outcomes.

The leadership team comprises experienced biotech operators. Kevin Kinsella serves as a founding partner; Jay Lichter holds the role of President and CEO; Sergio Duron is Chief Scientific Officer; and Sanford J. Madigan is Senior Vice President. This composition suggests COI Pharma relies on senior domain expertise to evaluate and advance pharmaceutical opportunities rather than scaling internal R&D headcount.

Public information about the company's pipeline, revenue model, partnerships, and product portfolio is severely limited. The corporate website contains only a cookie consent notice with no substantive disclosures, and no funding rounds, customer relationships, partnerships, regulatory milestones, or revenue figures are documented in the available source material. As a result, the company's current scale, capitalization, and commercial posture cannot be independently verified from public sources.

Short descriptiontext

COI Pharmaceuticals is a San Diego-based venture-pharma entity founded in 2013, operating with 11-50 employees under an experienced biotech leadership team to develop or hold pharmaceutical assets for partnership or spin-out.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture pharma, pharmaceutical development, drug development, biopharmaceutical research, clinical therapeutics
Industry4 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Industrial Organic Chemicals2860
Product category
Pharmaceuticals
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

COI Pharmaceuticals is a venture-pharma company founded in 2013 and based in San Diego that develops pharmaceutical assets. The company operates as a small drug development entity (11-50 employees) focused on advancing therapeutic candidates through the pharmaceutical value chain.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Pharmaceutical Drug Development Pipeline
CategoryPharmaceuticals
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

COI Pharmaceuticals

Pharmaceuticalscoipharma.com

COI Pharmaceuticals is a San Diego-based venture-pharma entity founded in 2013, operating with 11-50 employees under an experienced biotech leadership team to develop or hold pharmaceutical assets for partnership or spin-out.

What COI Pharmaceuticals does

COI Pharmaceuticals, operating as COI Pharma, is a venture-pharma entity headquartered in San Diego, California, founded in 2013. The company operates with a small team of 11-50 employees and is structured as a private for-profit enterprise. The "venture-pharma" designation indicates the company functions as a pharmaceutical venture creation, asset-holding, or development platform rather than a vertically integrated commercial-stage drug developer — a structure typical of entities that identify, incubate, and progress therapeutic programs toward partnership, licensing, or spin-out outcomes.

The leadership team comprises experienced biotech operators. Kevin Kinsella serves as a founding partner; Jay Lichter holds the role of President and CEO; Sergio Duron is Chief Scientific Officer; and Sanford J. Madigan is Senior Vice President. This composition suggests COI Pharma relies on senior domain expertise to evaluate and advance pharmaceutical opportunities rather than scaling internal R&D headcount.

Public information about the company's pipeline, revenue model, partnerships, and product portfolio is severely limited. The corporate website contains only a cookie consent notice with no substantive disclosures, and no funding rounds, customer relationships, partnerships, regulatory milestones, or revenue figures are documented in the available source material. As a result, the company's current scale, capitalization, and commercial posture cannot be independently verified from public sources.

COI Pharmaceuticals firmographics

Firmographics
Name
COI Pharmaceuticals
Website
https://coipharma.com
Company type
Private
Founded year
2013
Headcount range
11–50 employees
Short description
COI Pharmaceuticals is a San Diego-based venture-pharma entity founded in 2013, operating with 11-50 employees under an experienced biotech leadership team to develop or hold pharmaceutical assets for partnership or spin-out.
Ownership category
akta.pro rank

COI Pharmaceuticals industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Venture pharma
  • Pharmaceutical development
  • Drug development
  • Biopharmaceutical research
  • Clinical therapeutics

Where COI Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

COI Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

COI Pharmaceuticals product offering

Product offering

Core offering

COI Pharmaceuticals is a venture-pharma company founded in 2013 and based in San Diego that develops pharmaceutical assets. The company operates as a small drug development entity (11-50 employees) focused on advancing therapeutic candidates through the pharmaceutical value chain.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Drug Development Pipeline

Companies that use COI Pharmaceuticals

Customer profile

Ideal customer profiles1 record

COI Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

COI Pharmaceuticals partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

COI Pharmaceuticals competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

COI Pharmaceuticals social profiles

Digital presence

COI Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

COI Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

COI Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

COI Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about COI Pharmaceuticals

What does COI Pharmaceuticals do?

COI Pharmaceuticals is a venture-pharma company founded in 2013 and based in San Diego that develops pharmaceutical assets. The company operates as a small drug development entity (11-50 employees) focused on advancing therapeutic candidates through the pharmaceutical value chain.

When was COI Pharmaceuticals founded?

COI Pharmaceuticals was founded in 2013. It employs 11 to 50 people.

Where is COI Pharmaceuticals based?

COI Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

Does COI Pharmaceuticals have an API?

No public API is recorded for COI Pharmaceuticals.

What industry is COI Pharmaceuticals in?

COI Pharmaceuticals's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAHAA, Small-Molecule API Process Development & Route Scouting. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAvalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth CompanyAvalon Ventures and COI Pharmaceuticals announced that Sitari Pharmaceuticals and Silarus Therapeutics achieved lead declaration milestones, and PDI Therapeutics was formed to develop immune-oncology therapies. Financial terms were not disclosed, and PDI will receive up to $10 million in Series A financing and R&D support.PR NewswireAvalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth CompanyAvalon Ventures and COI Pharmaceuticals announced that Sitari Pharmaceuticals and Silarus Therapeutics, both formed under their collaboration with GlaxoSmithKline, have achieved their first milestones by completing lead declaration and establishing a path to identify a clinical candidate. The companies also announced the formation of PDI Therapeutics as the eighth company under this collaboration, which will develop antibody inhibitors targeting protein disulfide isomerases for immune-oncology therapies, with access to up to $10 million in Series A financing and R&D support from Avalon and GSK. GSK retains the option to acquire each company upon identification of a clinical candidate, otherwise Avalon retains ownership and the company may pursue other strategic transactions.FinSMEsSitari Pharmaceuticals Raises $10M in Series A FinancingSitari Pharmaceuticals raised $10M in Series A financing from Avalon Ventures and GlaxoSmithKline. The funds will support R&D for celiac disease treatments targeting the TG2 pathway. GSK has an option to acquire the company upon identifying a clinical candidate.VC News DailySitari Pharmaceuticals Inks $10M inSeries ASitari Pharmaceuticals has raised $10 million in Series A financing from Avalon Ventures and GSK to develop novel treatments for celiac disease, becoming the first company launched under the Avalon-GSK collaboration. The company is targeting the Transglutaminase 2 (TG2) pathway and was founded based on intellectual property in-licensed from Stanford professor Chaitan Khosla's laboratory. GSK holds an option to acquire Sitari upon identification of a clinical candidate.